Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells

Nuclear Medicine and Biology
Tapan K NayakR W Atcher

Abstract

Advance clinical cancer therapy studies of patients treated with somatostatin receptor (sstr)-targeted [DOTA(0)-Tyr(3)]octreotide (DOTATOC) labeled with low-linear-energy-transfer (LET) beta(-)-emitters have shown overall response rates in the range of 15-33%. In order to improve outcomes, we sought to compare the therapeutic effectiveness of sstr-targeted high-LET alpha-emitting (213)Bi to that of low-LET beta(-)-emitting (177)Lu by determining relative biological effectiveness (RBE) using the external gamma-beam of (137)Cs as reference radiation. Sstr-expressing human pancreatic adenocarcinoma Capan-2 cells and A549 control cells were used for this study. The effects of different radiation doses of (213)Bi and (177)Lu labeled to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid and sstr-targeted DOTATOC were investigated with a clonogenic cell survival assay. Apoptosis was measured using the Cell Death Detection ELISA(PLUS) 10x kit. Using equimolar DOTATOC treatment with concurrent irradiation with a (137)Cs source as reference radiation, the calculated RBE of [(213)Bi]DOTATOC was 3.4, as compared to 1.0 for [(177)Lu]DOTATOC. As measured in terms of absorbance units, [(213)Bi]DOTATOC caused a 2.3-fold-greater release o...Continue Reading

References

Dec 1, 1982·International Journal of Radiation Oncology, Biology, Physics·C A TobiasT C Yang
Mar 1, 1995·Radiation and Environmental Biophysics·J H HendryA Merritt
May 1, 1993·International Journal of Radiation Biology·D T GoodheadR Cox
Mar 1, 1993·Medical Physics·John L HummG T Chen
Aug 6, 1999·Frontiers in Neuroendocrinology·Y C Patel
Nov 7, 1999·European Journal of Nuclear Medicine·Andreas OtteJ Muller
May 8, 2001·International Journal of Cancer. Journal International Du Cancer·Marion de JongEric P Krenning
Sep 28, 2001·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·D MaD A Scheinberg
Nov 17, 2001·Science·M R McDevittD A Scheinberg
Jan 5, 2002·Health Physics·Thomas B Borak
Feb 21, 2002·Cancer Investigation·Derek C RadiskyMina J Bissell
May 11, 2002·European Journal of Nuclear Medicine and Molecular Imaging·Tilmann SchumacherHelmut Maecke
Jun 7, 2003·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·S M RizviS Sarkar
Aug 16, 2003·Endocrine Reviews·Jean Claude Reubi
Jan 1, 1960·Annual Review of Nuclear Science·T ALPER
Jan 20, 2004·European Journal of Nuclear Medicine and Molecular Imaging·Marcus HenzeUwe Haberkorn
Feb 7, 2004·Science·Derek C Radisky, Mina J Bissell
May 22, 2004·Annals of the New York Academy of Sciences·Eric P KrenningMarion de Jong
May 27, 2004·Radiation Research·Bieke LambertAndreas Otte
Jun 3, 2004·Nature Reviews. Drug Discovery·Diane E MilenicMartin W Brechbiel
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey P NorenbergLarry K Kvols
Mar 4, 2006·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

Citations

Mar 18, 2009·The Journal of Biological Chemistry·Subramanian SenthivinayagamBasabi Rana
Feb 6, 2009·Nuclear Medicine Communications·Elisa GrassiGiovanni Borasi
Apr 26, 2014·Clinical and Translational Imaging : Reviews in Nuclear Medicine and Molecular Imaging·Sander M BisonMarion de Jong
Dec 2, 2009·Expert Opinion on Drug Delivery·Gábor Mezo, Marilena Manea
Apr 17, 2015·BioMed Research International·Caiyun Xu, Hong Zhang
Feb 25, 2015·Cancer Biotherapy & Radiopharmaceuticals·Ashutosh DashFurn F Russ Knapp
Jul 28, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Giuseppe Lo RussoMarina Chiara Garassino
Mar 31, 2010·Seminars in Nuclear Medicine·Ekaterina Dadachova
Aug 14, 2018·The British Journal of Radiology·Deborah PencharzShaunak Navalkissoor
Jul 30, 2010·Physics in Medicine and Biology·F Van den HeuvelS Nuyts
Aug 31, 2019·Current Treatment Options in Oncology·Grace Kong, Rodney J Hicks
Sep 6, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Romain EychenneNicolas Lepareur
Jul 29, 2008·Physics in Medicine and Biology·Helena UusijärviEva Forssell-Aronsson
Jun 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·M MiedererMarkus Essler
Mar 31, 2019·Molecular Cancer Therapeutics·Tania A Rozgaja StallonsJulien J Torgue

Related Concepts

Carcinoma, Cribriform
Alpha Radiation
Beta Particle
Bismuth
Cell Survival
Dose-Response Relationship, Radiation
Lutetium
Malignant Neoplasm of Pancreas
Radioisotopes
Radiotherapy Dosage

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

© 2021 Meta ULC. All rights reserved